Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5420204 | 0.92 | KDM4E (0.49) | MEN1KMT2AHPGDKDM4EMAPT | |
| SCHEMBL5414765 | 0.87 | PDE3B (0.47) | PDE3BPDE3AKDM4EMAPTALDH1A1 | |
| SCHEMBL2327375 | 0.85 | KMT2A (0.53) | MEN1KMT2AHPGDKDM4EMAPT | |
| SCHEMBL6369995 | 0.85 | PDE3B (0.44) | PDE3BPDE3AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL2324360 | 0.82 | HPGD (0.47) | MEN1KMT2AHPGDPDE3BPDE3A | |
| SCHEMBL6486299 | 0.80 | HPGD (0.48) | MEN1KMT2AHPGDPDE3BPDE3A | |
| SCHEMBL5420556 | 0.79 | PDE3B (0.46) | MEN1KMT2APDE3BPDE3AMAPT | |
| SCHEMBL2324458 | 0.79 | MEN1 (0.46) | MEN1KMT2AHPGDKDM4EMAPT | |
| SCHEMBL6370131 | 0.79 | PDE3B (0.44) | MEN1KMT2APDE3BPDE3AMAPT | |
| SCHEMBL2324732 | 0.79 | HPGD (0.45) | MEN1KMT2AHPGDKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196202-B2 | 1-aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2007-03-27 | — | — | US | claimed |
| EP-1404656-B9 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AG (DE) | 2005-10-19 | — | — | EP | claimed |
| US-20050143439-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-30 | — | — | US | claimed |
| EP-1404656-B1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AG (DE) | 2005-05-18 | — | — | EP | claimed |
| US-20030125550-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2003-07-03 | — | — | US | claimed |
| US-7196202-B2 | 1-aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2007-03-27 | — | — | US | disclosed |
| EP-1404656-B9 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AG (DE) | 2005-10-19 | — | — | EP | disclosed |
| US-20050143439-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-30 | — | — | US | disclosed |
| US-6903126-B2 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2005-06-07 | — | — | US | disclosed |
| EP-1404656-B1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING MICROGLIA-ACTIVATION ASSOCIATED DISEASES SUCH AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMMUNE DISEASES | SCHERING AG (DE) | 2005-05-18 | — | — | EP | disclosed |
| US-20030125550-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125550-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | MSR1, ARG2, ARG1 | MEN1 4451/4885KMT2A 2370/4885HPGD 729/4885 |
| US-20050143439-A1 | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | MSR1, ARG2, CYBB | MEN1 4501/4885KMT2A 2159/4885HPGD 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.